echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > "Innovative Drug One Brother" is amazing!

    "Innovative Drug One Brother" is amazing!

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 22, the clinical application of Hengrui Medicine's 2 Class 1 new drugs was accepted by CDE.
    In addition, it was the first company to submit 10% fat emulsion (OO)/5.
    5% amino acid (15)/glucose (20%) injection under the new registration classification.
    Liquid listing application
    .


    According to data from Meinenet, in the past week, Hengrui Medicine has 7 new drugs (6 of which are Class 1 new drugs) for clinical application


    Source: CDE official website

    On December 22, Hengrui Medicine's clinical application for 2 new category 1 drugs and the marketing application for 1 category 4 generic drugs were accepted by the CDE
    .


    At present, only Baxter’s 10% fat emulsion (OO)/5.


    Innovative drugs and first generic drugs are the focus of Hengrui Pharmaceuticals.


    On December 17-23, Hengrui Medicine applied for listing/clinical varieties

    On December 17-23, Hengrui Medicine applied for listing/clinical varieties

    Source: Meinenet MED2.


    Among the 6 Class 1 new drugs, SHR-1816 injection and HRS-2261 tablets were submitted for clinical application in China for the first time


    Among the new drugs not declared for the first time, SHR0302 tablets are a selective inhibitor of JAK1 kinase, and the indications for active rheumatoid arthritis and atopic dermatitis are in phase III clinical trials; SHR-1316 injection is PD-L1 monoclonal antibody Indications such as extensive-stage small cell lung cancer have entered phase III clinical trials; SHR-1501 for injection is an interleukin-15 (IL-15) fusion protein, and advanced malignant tumor indications are in phase I clinical trials; for injection SHR-A1811 is an ADC drug targeting Her2, and its indications for advanced non-small cell lung cancer are in phase I/II clinical trials


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.